Therapeutic Asset Ratings

622 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
18f-flt Breast Cancer	University of Pennsylvania	P3	CCC (54)
azd5305 Breast Cancer	AstraZeneca	P3	CCC (54)
Bcd-178 Breast Cancer	Biocad	P3	CCC (54)
Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)- Breast Cancer	Relay Therapeutics, Inc.	P3	CCC (54)
Bl-M07D1 Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	CCC (54)
fs-1502 Breast Cancer	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P3	CCC (54)
Hemay022 Breast Cancer	Tianjin Hemay Pharmaceutical Co., Ltd	P3	CCC (54)
Jskn003 Breast Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	CCC (54)
MITOMYCIN C Breast Cancer	UNICANCER	P3	CCC (54)
Palazestrant Breast Cancer	Olema Pharmaceuticals, Inc.	P3	CCC (54)
pf-05212384 Breast Cancer	Celcuity Inc	P3	CCC (54)
pf-07248144 Breast Cancer	Pfizer	P3	CCC (54)
sim0270 Breast Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P3	CCC (54)
Hrs-6209 Breast Cancer	Atridia Pty Ltd.	P2	CCC (54)
Ibrutinib Breast Cancer	The Netherlands Cancer Institute	P2	CCC (54)
Imlunestrant Breast Cancer	Fudan University	P2	CCC (54)
Luvixasertib Breast Cancer	Canadian Cancer Trials Group	P2	CCC (54)
CETIRIZINE Breast Cancer	Maryam Lustberg	P3	CCC (53)
Mifepristone Breast Cancer	Memorial Sloan Kettering Cancer Center	P3	CCC (53)
DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2 Breast Cancer	Novartis Pharmaceuticals	P2	CCC (53)
Entrectinib Breast Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Fexagratinib Breast Cancer	UNICANCER	P2	CCC (53)
FFNP Breast Cancer	University of Wisconsin, Madison	P2	CCC (53)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Breast Cancer	Ministry of Health, Saudi Arabia	P2	CCC (53)
Ganetespib Breast Cancer	University of Chicago	P2	CCC (53)

Showing 176 to 200 of 622 assets

PreviousPage 8 of 25Next